Physician profile
Joanne Daniel-Saunders
NPI 1164536918
$601.75
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $85.17 · 2021: $46.16 · 2022: $105 · 2023: $81.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $90.25 | 2022 | |
| Glaxosmithkline, LLC. | $77.24 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $76.21 | 2019-2020 | |
| Abbott Laboratories | $55.64 | 2021-2023 | Proclaim |
| Novo Nordisk INC | $55.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $41.39 | 2019-2020 | |
| Lilly USA, LLC | $37.96 | 2019-2022 | |
| Pfizer INC. | $35.27 | 2019-2021 | |
| Astellas Pharma US INC | $31.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.70 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.63 | 2020 | |
| Shire North American Group INC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Daniel-Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.